New drug cocktail offers hope for rare, aggressive cancer

NCT ID NCT07518602

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Apr 10, 2026 · Last updated Apr 28, 2026 · Updated 4 times

Summary

This study tests a combination of three drugs (chidamide, sintilimab, and bevacizumab) in 34 people with advanced extrapulmonary neuroendocrine carcinoma that has worsened after standard first-line therapy. The goal is to see if this treatment can shrink tumors or slow disease progression. Participants will receive the drugs intravenously and be monitored for side effects and response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)